Advert - Teva

DuoResp Spiromax advertisement on BMJ hosted website

For placing an advertisement for DuoResp Spiromax (budesonide/formoterol fumarate) that was misleading and inconsistent with the summary of product characteristics, Teva was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 3.2 - Promoting a medicine in a manner which was inconsistent with the particulars listed in its summary of product characteristics

Clause 7.2 - Making misleading claims

Clause 9.1 - Failing to maintain high standards